Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2012

01.10.2012 | General Gynecology

Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model

verfasst von: Xiujuan Li, Yanyan Bao, Peng Fang, Yaping Chen, Zhongdong Qiao

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To study the influence of mifepristone on the expression of cyclooxygenase 2 (COX-2) protein and COX-2 mRNA and then to evaluate the mechanism.

Methods

After the establishment of 30 mice endometriosis models, the mice were randomly divided into six groups with 5 mice each group and assigned to experimental and control groups of 1-, 4- and 6-week circle according to whether mifepristone (0.13 mg d−1) was taken or not. Small animal optical imaging system was used to detect the fluorescent intensity of the ectopic tissue. Reverse transcript-polymerase chain reaction and western blot was used to examine COX-2 protein and COX-2 mRNA expression. ELISA was used to examine concentration of PGE2 in serum.

Result(s)

Mifepristone could not affect the fluorescent intensity of the ectopic endometrium after it was taken 1, 4, and 6 (P > 0.05). However, it could decrease the transcription of COX-2 mRNA in the 1 and 4 week groups (P < 0.05), while the difference in the 6 week group was not significant (P > 0.05). It could decrease the expression of COX-2 protein after it was taken 4 and 6 weeks (P < 0.05). The serous PGE2 in the trial groups was lower than that in the control groups, but the difference was not significant (P > 0.05).

Conclusion(s)

This study showed that mifepristone could not affect the size of the ectopic endometrium, but it could decrease the transcription of COX-2 gene and then reduce the expression of COX-2 protein and its product PGE2 which is an important factor which mediate pain. This maybe another mechanism that mifepristone takes effect through anti-inflammatory path.
Literatur
2.
Zurück zum Zitat Song JY, Peter R, Robert M, Frank M, Ian SF (1996) Uterus and endometrium: effect of high dose progestogens on white cells and necrosis in human endometrium. Hum Reprod 11(8):1713–1718PubMedCrossRef Song JY, Peter R, Robert M, Frank M, Ian SF (1996) Uterus and endometrium: effect of high dose progestogens on white cells and necrosis in human endometrium. Hum Reprod 11(8):1713–1718PubMedCrossRef
3.
Zurück zum Zitat Benagiano G, Bastianelli C, Farris M (2008) Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother 9(14):2473–2485PubMedCrossRef Benagiano G, Bastianelli C, Farris M (2008) Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother 9(14):2473–2485PubMedCrossRef
4.
Zurück zum Zitat Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS (1996) Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 65(1):23–28PubMed Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS (1996) Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 65(1):23–28PubMed
5.
Zurück zum Zitat Baird DT, Brown A, Critchleym HOD, Williams AR, Lin S, Cheng L (2003) Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 18(1):61–68PubMedCrossRef Baird DT, Brown A, Critchleym HOD, Williams AR, Lin S, Cheng L (2003) Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 18(1):61–68PubMedCrossRef
6.
Zurück zum Zitat Jiang J, Wu RF, Wang ZH, Sun HC, Xu Z, Xiu HM (2002) Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 77(5):995–1000PubMedCrossRef Jiang J, Wu RF, Wang ZH, Sun HC, Xu Z, Xiu HM (2002) Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 77(5):995–1000PubMedCrossRef
7.
Zurück zum Zitat Hirata T, Osuga Y, Yoshino O, Hirota Y, Harada M, Takemura Y, Morimoto C, Koga K, Yano T, Tsutsumi O, Taketani Y (2005) Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein. Hum Reprod 20(8):2092–2096PubMedCrossRef Hirata T, Osuga Y, Yoshino O, Hirota Y, Harada M, Takemura Y, Morimoto C, Koga K, Yano T, Tsutsumi O, Taketani Y (2005) Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein. Hum Reprod 20(8):2092–2096PubMedCrossRef
8.
Zurück zum Zitat Ota H, Igarashi S, Sasaki M, Tanaka T (2001) Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16(3):561–566PubMedCrossRef Ota H, Igarashi S, Sasaki M, Tanaka T (2001) Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16(3):561–566PubMedCrossRef
9.
Zurück zum Zitat Wu MH, Wang CA, Lin CC, Chen LC, Chang WC, Tsai SJ (2005) Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 90(1):286–295PubMedCrossRef Wu MH, Wang CA, Lin CC, Chen LC, Chang WC, Tsai SJ (2005) Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 90(1):286–295PubMedCrossRef
10.
Zurück zum Zitat Tamura M, Deb S, Sebastian S, Okamura K, Bulun SE (2004) Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 81(5):1351–1356PubMedCrossRef Tamura M, Deb S, Sebastian S, Okamura K, Bulun SE (2004) Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 81(5):1351–1356PubMedCrossRef
11.
Zurück zum Zitat Li J, Lu Y, Ma D (2002) Cyclooxyenase-2 expression in endometrium carcinoma. Zhonghua Fu Chan Ke Za Zhi 37(7):408–410PubMed Li J, Lu Y, Ma D (2002) Cyclooxyenase-2 expression in endometrium carcinoma. Zhonghua Fu Chan Ke Za Zhi 37(7):408–410PubMed
12.
Zurück zum Zitat Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N, Yamamoto T, Honda M (2002) Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 48(1):50–56PubMedCrossRef Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N, Yamamoto T, Honda M (2002) Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 48(1):50–56PubMedCrossRef
13.
Zurück zum Zitat Chishima F, Hayakawa S, Hirata Y, Nagai N, Kanaeda T, Tsubata K, Satoh K (2000) Peritoneal and peripheral B-1-cell populations in patients with endometriosis. J Obstet Gynaecol Res 26(2):141–149PubMedCrossRef Chishima F, Hayakawa S, Hirata Y, Nagai N, Kanaeda T, Tsubata K, Satoh K (2000) Peritoneal and peripheral B-1-cell populations in patients with endometriosis. J Obstet Gynaecol Res 26(2):141–149PubMedCrossRef
14.
Zurück zum Zitat Attar E, Bulun SE (2006) Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 12(1):49–56PubMedCrossRef Attar E, Bulun SE (2006) Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 12(1):49–56PubMedCrossRef
15.
Zurück zum Zitat Bulun SE, Zeitoun KM, Takayama K, Sasano H (2000) Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J Mol Endocrinol 25(1):35–42PubMedCrossRef Bulun SE, Zeitoun KM, Takayama K, Sasano H (2000) Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J Mol Endocrinol 25(1):35–42PubMedCrossRef
16.
Zurück zum Zitat Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE (1998) Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 83(12):4474–4480PubMedCrossRef Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE (1998) Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 83(12):4474–4480PubMedCrossRef
17.
Zurück zum Zitat Osteen KG, Bruner KL, Sharpe-Timms KL (1996) Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol 14(3):247–255PubMedCrossRef Osteen KG, Bruner KL, Sharpe-Timms KL (1996) Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol 14(3):247–255PubMedCrossRef
18.
Zurück zum Zitat Dassen H, Punyadeera C, Kamps R, Delvoux B, Van Langendonckt A, Donnez J, Husen B, Thole H, Dunselman G, Groothuis P (2007) Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod 22(12):3148–3158PubMedCrossRef Dassen H, Punyadeera C, Kamps R, Delvoux B, Van Langendonckt A, Donnez J, Husen B, Thole H, Dunselman G, Groothuis P (2007) Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod 22(12):3148–3158PubMedCrossRef
19.
Zurück zum Zitat Wu Y, Guo SW (2006) Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 62(4):193–205PubMedCrossRef Wu Y, Guo SW (2006) Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 62(4):193–205PubMedCrossRef
20.
Zurück zum Zitat Mei L, Bao J, Tang L, Zhang C, Wang H, Sun L, Ma G, Huang L, Yang J, Zhang L, Liu K, Song C, Sun H (2010) A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci 39(5):421–427PubMedCrossRef Mei L, Bao J, Tang L, Zhang C, Wang H, Sun L, Ma G, Huang L, Yang J, Zhang L, Liu K, Song C, Sun H (2010) A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci 39(5):421–427PubMedCrossRef
21.
Zurück zum Zitat Guo SW, Liu M, Shen F, Liu X (2011) Use of mifepristone to treat endometriosis: a review of clinical trials and trial-like studies conducted in China. Women Health (Lond Engl) 7(1):51–70CrossRef Guo SW, Liu M, Shen F, Liu X (2011) Use of mifepristone to treat endometriosis: a review of clinical trials and trial-like studies conducted in China. Women Health (Lond Engl) 7(1):51–70CrossRef
22.
Zurück zum Zitat Kettel LM, Murphy AA, Morales AJ, Yen SS (1998) Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 178(6):1151–1156PubMedCrossRef Kettel LM, Murphy AA, Morales AJ, Yen SS (1998) Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 178(6):1151–1156PubMedCrossRef
Metadaten
Titel
Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model
verfasst von
Xiujuan Li
Yanyan Bao
Peng Fang
Yaping Chen
Zhongdong Qiao
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2379-2

Weitere Artikel der Ausgabe 4/2012

Archives of Gynecology and Obstetrics 4/2012 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.